TY - JOUR
T1 - Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma
AU - Zucchi, Alessandro
AU - Novara, Giacomo
AU - Costantini, Elisabetta
AU - Antonelli, Alessandro
AU - Carini, Marco
AU - Carmignani, Giorgio
AU - Cunico, Sergio Cosciani
AU - Fontana, Dario
AU - Longo, Nicola
AU - Martignoni, Guido
AU - Minervini, Andrea
AU - Mirone, Vincenzo
AU - Porena, Massimo
AU - Roscigno, Marco
AU - Schiavina, Riccardo
AU - Simeone, Claudio
AU - Simonato, Alchiede
AU - Siracusano, Salvatore
AU - Terrone, Carlo
AU - Ficarra, Vincenzo
PY - 2012/4
Y1 - 2012/4
N2 - OBJECTIVES: • To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. • Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS: • From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. • Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surgery. RESULTS: • At a median (interquartile range) follow-up of 39.2 (21.7-72) months, 81 (14%) patients had experienced disease progression and 63 (11%) patients had died from disease; the 5-year RFS estimate was 85.5%. • In multivariable analysis, pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.9; P = 0.007) and Fuhrman nuclear grade (pooled P = 0.039) were all independent predictors of RFS; the 5-year CSS estimate was 87.9%. • In Cox multivariable analysis, an independent predictive role was reconfirmed for mode of presentation (pooled P = 0.038), pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.4; P = 0.049) and Fuhrman nuclear grade (pooled P = 0.037). CONCLUSIONS: • Patients with pRCC have a low risk of tumour recurrence and cancer-related death after surgery. • Fuhrman nuclear grade was found to be a stronger predictor of both RFS and CSS, whereas only a non-statistically significant trend was found for the 2009 pathological T stage.
AB - OBJECTIVES: • To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. • Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS: • From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. • Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surgery. RESULTS: • At a median (interquartile range) follow-up of 39.2 (21.7-72) months, 81 (14%) patients had experienced disease progression and 63 (11%) patients had died from disease; the 5-year RFS estimate was 85.5%. • In multivariable analysis, pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.9; P = 0.007) and Fuhrman nuclear grade (pooled P = 0.039) were all independent predictors of RFS; the 5-year CSS estimate was 87.9%. • In Cox multivariable analysis, an independent predictive role was reconfirmed for mode of presentation (pooled P = 0.038), pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.4; P = 0.049) and Fuhrman nuclear grade (pooled P = 0.037). CONCLUSIONS: • Patients with pRCC have a low risk of tumour recurrence and cancer-related death after surgery. • Fuhrman nuclear grade was found to be a stronger predictor of both RFS and CSS, whereas only a non-statistically significant trend was found for the 2009 pathological T stage.
KW - Papillary renal cell carcinoma
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=84860396898&partnerID=8YFLogxK
U2 - 10.1111/j.1464-410X.2011.10517.x
DO - 10.1111/j.1464-410X.2011.10517.x
M3 - Article
SN - 1464-4096
VL - 109
SP - 1140
EP - 1146
JO - BJU International
JF - BJU International
IS - 8
ER -